
Patients who receive stimulation at different parts of the brain may reap benefits.

Patients who receive stimulation at different parts of the brain may reap benefits.

Although we have made strides in adopting technology to combat diversion, the uptake of advanced technology is slow and steady.

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.

Health coaches supporting remote pharmacist services can improve diabetes disparities.

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.

A study published in the American Journal of Preventive Cardiology found a systematic educational approach overcomes obstacles in prescribing guideline-directed antihyperglycemic medications.

According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.

Because alcohol is a driver of HIV-associated comorbidities, the reduction interventions may improve the health of people with HIV.

From newsworthy moments to groundbreaking research, these were the most-read specialty pharmacy-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read oncology-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read pediatrics-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read health systems-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most watched videos on Pharmacy Focus in 2023.

From newsworthy moments to groundbreaking research, these were the most-read coronavirus-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most listened-to podcasts on Pharmacy Focus in 2023.

From newsworthy moments to groundbreaking research, these were the most-read reimbursement-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read skin cancer-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read pneumococcal-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read cardiovascular-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read Clostridioides difficile-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read heart failure-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read student-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read respiratory syncytial virus-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read community pharmacy-related articles from Pharmacy Times in 2023.

In a study, most patients had specified SBP targets of less than 160 mmHg and all patients attained goal within a relatively short period of time.

With gastrointestinal-based adverse effectss for rivastigmine and other cholinesterase inhibitors, a weight of <50 and <55 kg respectively leads to an increased risk for toxicities.

The drug is the first medicine to be approved for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis that can be self-administered.